Cases
Hylands Assists CorrectSequence Therapeutics in Raising RMB 40 Million in Angel Series Financing
关注“浩天信和法律评论”，查看更多内容
CorrectSequence (Shanghai) Biotechnology Co., Ltd (hereinafter referred to as "CorrectSequence Therapeutics") is a start-up company dedicated to the use of gene editing technology for the treatment of human diseases, and has recently raised a substantial angel funding series of RMB 40 million. The current series of financing was co-led by Zoo Capital and New Alliance Capital, followed by Sequoia Capital China Fund and TF Capital, and an exclusive global perpetual license agreement was signed with University of Science and Technology Shanghai for a patent portfolio totaling over RMB 170 million.
Hylands has been engaged in the medical and health care services for many years with continuous efforts. Furthermore, with its extensive experience in intellectual property, corporate and investment, private equity, pharmaceutical and health care services, Hylands has continued to safeguard CorrectSequence Therapeutics in various aspects such as financing transactions and scientific research cooperation. In the future, CorrectSequence Therapeutics will, relying on the research platform jointly built by University of Shanghai for Science and Technology, Chinese Academy of Sciences and Wuhan University, develop breakthrough therapies for genetic diseases based on the next-generation gene editing system (base editing) to provide more diverse, effective and affordable novel treatments for patients with genetic/rare diseases. Hylands will further assist CorrectSequence Therapeutics in its efforts to combat diseases and benefit human health.
The legal service team for the Project consisted of Partner Han ZHOU, Partner Jie LI, Partner Wenjie JIANG, and Intern Xuan WANG.